AFFILIATIONS
1 Facultat de Biociències, Universitat Autònoma de Barcelona, Barcelona, Spain, MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
2 Facultat de Biociències, Universitat Autònoma de Barcelona, Barcelona, Spain, MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
3 MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
4 Myeloid Malignancies Research Group, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
5 Myeloid Malignancies Research Group, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
6 Hematology Department, ICO-Hospital Germans Trias i Pujol, IJC,, Badalona, Spain
7 Hematology Department, ICO-Hospital Germans Trias i Pujol, IJC,, Badalona, Spain
8 Hematology Department, ICO-Hospital Germans Trias i Pujol, IJC,, Badalona, Spain
9 Department of Hematology and Medical Oncology, INDIGHO laboratory, University Medical Center Göttingen (UMG), Göttingen, Germany
10 Department of Hematology and Medical Oncology, INDIGHO laboratory, University Medical Center Göttingen (UMG), Göttingen, Germany
11 Hospital Universitari Son Llàtzer, Hematology Department, Palma de Mallorca, Spain
12 Department of Hematology, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
13 Department of Hematology, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
14 Department of Hematology, Hospital Clinic, Barcelona, Spain, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
15 Microarrays Unit, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Badalona, Spain
16 MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
17 MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
18 MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
19 Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic, Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, United States
20 MDS Unit, Hematology, AOU Careggi - Department of Experimental and Clinical Medicine University of Florence, Florence, Italy
21 Humanitas University, Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy
22 Laboratory of Immunohematology and Glycobiology (IJC), Badalona, Spain, MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
23 Facultat de Biociències, Universitat Autònoma de Barcelona, Barcelona, Spain, MDS Research Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
ABSTRACT
Background & aims: One of the main features of myelodysplastic syndromes (MDS) is the risk of progression to higher-risk disease and/or acute myeloid leukemia (AML). Patients classified as lower-risk by the IPSS-R generally follow an indolent course, yet a subset experiences disease evolution through mechanisms that remain poorly defined. Longitudinal molecular monitoring may help identify these patients earlier than baseline-based risk scores alone. We studied whether the acquisition of molecular alterations (AMA) during follow-up impacts progression and survival in untreated low-risk MDS.
Methods: We performed targeted NGS on paired diagnosis and follow-up samples from 165 patients with low-risk MDS who had not received disease-modifying therapy between diagnosis and the follow-up sample analyzed (thereby excluding isolated del(5q) MDS eligible for lenalidomide and secondary MDS), with follow-up of ≥18 months or until progression. AMA was defined as appearance of a new variant, loss of a variant, or a change in variant allele frequency (VAF) greater than 10% of an existing mutation. Associations with progression and survival were tested with logistic regression and Cox proportional-hazards models.
Results: Over a median follow-up of 24 months (IQR: 14-36), 26.7% (44/165) of patients progressed to higher-risk MDS or AML. Notably, progressors were significantly younger than non-progressors (median age: 67 vs. 75 years, p<0.001). Among the 165 patients, 140 had detectable mutations at baseline and/or during follow-up and AMA occurred far more often among progressors than non-progressors (90.9% vs 57.9%; OR 10.2, p<0.001).
Importantly, not all molecular evolution carried equal weight. Progression occurred in only 7.3% of patients with no molecular change over time, compared with 23.5% when only the VAF of an existing mutation changed, 38.1% when a new mutation appeared, and 45.7% when several types of change occurred together. After adjusting for age, sex and baseline mutation burden, acquiring a new mutation remained an independent risk factor for progression (OR 10.4, P=0.002), while an isolated change in VAF or variant lost did not. This indicates that the emergence of new clones, rather than expansion of clones already present at diagnosis, is what drives disease progression in this cohort. Among these 140 patients, 82 new mutations across 29 different genes were acquired during follow-up, involving 40% of the patients. However, no single gene reached statistical significance on its own, though RUNX1 and CBL were more frequently seen among progressors.
Baseline mutational profile also shaped how disease evolved over time: patients with an SRSF2 mutation at diagnosis were markedly more likely to develop AMA during follow-up (68.2% vs 28.7%; OR 9.67, P=0.034), while patients whose only or founding mutation was in SF3B1 tended to remain molecularly stable (OR 0.20, p<0.001).
AMA was also associated with shorter overall survival (HR 3.58, P=0.005). This was driven specifically by the acquisition of new mutations, which remained an independent predictor of survival even after adjusting for age and IPSS-M (HR 2.82, P=0.0012), supporting the added prognostic value of longitudinal molecular monitoring beyond baseline risk stratification. We additionally observed that in 23% of patients, the dominant mutated clone at diagnosis was replaced by a different one during follow-up (most frequently U2AF1 being replaced by ASXL1). This clonal switch was itself associated with higher progression risk (OR 3.34, P=0.007) and shorter overall survival (HR 1.92, P=0.041), a phenomenon rarely characterized in an untreated low-risk MDS population.
Conclusions: We have studied the impact of AMA in the largest untreated low-risk MDS cohorts with longitudinal molecular data reported to date to our knowledge. The results show that AMA is associated with poorer prognosis, and this increased risk could be driven by the emergence of new mutations and replacement of the dominant clone, not by simple expansion of pre-existing ones. Baseline SRSF2 and SF3B1 status helped to identify which patients were more likely to evolve, and molecular follow-up added prognostic information beyond IPSS-M. Together, these findings support incorporating longitudinal molecular monitoring into the clinical follow-up of low-risk MDS.
Acknowledgments: Bristol Myers Squibb (PI-13279-IIT), PI23/00007, 2021SGR00560(GRC).